Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum

Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company, announced its participation in the JMP Securities Hematology & Oncology Forum on June 18, 2020. CEO Troy Wilson will engage in a fireside chat at 10:40 a.m. ET. The virtual event runs from June 18-19, and interested parties can access a live audio webcast via Kura's website, with an archived replay available for 30 days after the event.

Kura's pipeline includes drug candidates targeting cancer pathways, with its lead candidate being tipifarnib for HRAS mutant head and neck squamous cell carcinoma.

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology & Oncology Forum (Virtual). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat on Thursday, June 18, 2020 at 10:40 a.m. ET / 7:40 a.m. PT. The virtual forum will be held from June 18-19, 2020.

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2A(MLL) protein-protein interaction currently in a Phase 1/2A clinical trial, KOMET-001, in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

What is Kura Oncology's participation in the JMP Securities Forum?

Kura Oncology will participate in the JMP Securities Hematology & Oncology Forum on June 18, 2020.

When is the Kura Oncology fireside chat scheduled?

The fireside chat with CEO Troy Wilson is scheduled for June 18, 2020, at 10:40 a.m. ET.

How can I listen to the Kura Oncology fireside chat?

You can listen to the Kura Oncology fireside chat live on their website, with a replay available for 30 days.

What drugs are in Kura Oncology's pipeline?

Kura has two leading candidates: tipifarnib for HRAS mutant head and neck cancer and KO-539 for acute myeloid leukemia.

What is the significance of Kura Oncology's participation in this event?

Kura's participation highlights its commitment to advancing precision medicines in oncology.